Investor Centre

Pharmaxis 2020 Directors' Report and Annual Financial Statements

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced an accelerated timeline on payment of the initial tranche of a US$10 million Bronchitol launch milestone following negotiation with its US licensee Chiesi Farmaceutici S.p.A. (Chiesi). US$7 million of the milestone will now be payable by Chiesi upon US approval of Bronchitol by the Food and Drug Administration (FDA) who have advised a Goal Action Date of 1 November 2020. Another US$3 million will remain payable on shipment by Pharmaxis of commercial launch stock in the first quarter of 2021. 

Shareholder update for the quarter ended 30 June 2020

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS), the leading developer of therapeutics targeting lysyl oxidase enzymes to treat fibrosis and cancer, announced it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. The protocol incorporates a one-month dose escalation phase followed by 6 months’ treatment in an open label study of patients who are not on a JAK inhibitor.  The study is planned to commence in Q4 2020 and expected to conclude in 2022.

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that the U.S. Food & Drug Administration (FDA) has granted orphan-drug designation for its oral pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis.